Emerging clinical evidence also suggests that gut microbiota may play a mechanistic or modulatory role in the therapeutic efficacy of GLP-1 receptor agonists in T2DM, although findings remain heterogeneous across studies. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.